Patrick van der Torre

Mr. Patrick van der Torre

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2016 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
KBKatja I Braam
Katja I Braam
PTPatrick van der Torre
Patrick van der Torre
TTTim Takken
Tim Takken
MVMargreet A Veening
Margreet A Veening
EBEline van Dulmen-Den Broeder
Eline van Dulmen-Den Broeder
GKGertjan Jl Kaspers
Gertjan Jl Kaspers

1 February 2018 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
SOSapna Oberoi
Sapna Oberoi
PRPaula D. Robinson
Paula D. Robinson
DCDanielle Cataudella
Danielle Cataudella
SCS. Nicole Culos-Reed
S. Nicole Culos-Reed
HDHailey Davis
Hailey Davis
LSLillian Sung
Lillian Sung

25 February 2009 in Psycho-Oncology
Verified
Journal Article
Open access
PDF file
TTTim Takken
Tim Takken
PTPatrick van der Torre
Patrick van der Torre
MZMarlies Zwerink
Marlies Zwerink
EHErik H. Hulzebos
Erik H. Hulzebos
MBMarc Bierings
Marc Bierings
JNJanjaap van der Net
Janjaap van der Net
Objective: The aim of this study was to develop a 12‐week exercise training program (comprising aerobic and strength exercises), and to study the feasibility and efficacy of this exercise program in children who survived acute lymphoblastic leukemia.Sample and methods: A 12‐week exercise program was developed and tested for feasibility in nine children who survived cancer.Results: From the 16 eligible children for the intervention, 9 participated, while 4 were able to complete the entire program. Feasibility of the program was scored by five children, two of them reported the program as being too demanding. The participating physiotherapists were satisfied with training methodology and training progress. The efficacy of the program on muscle strength, exercise capacity, functional mobility and fatigue showed no significant differences between pre and post training.Conclusion: In designing a community‐based exercise training program, not only the stage of the disease needs to be considered, but more so the age of the children, the variety of exercises, the location of implementation and even more importantly the views and motivation of the parents concerning the execution of an exercise training program. A careful balance between these parameters could lead to a greater adherence and by that, to a better outcome of these programs. Copyright © 2009 John Wiley & Sons, Ltd.

30 April 2013
Verified
Reference Entry
Closed access
KBKatja I Braam
Katja I Braam
PTPatrick van der Torre
Patrick van der Torre
TTTim Takken
Tim Takken
MVMargreet A Veening
Margreet A Veening
EBEline van Dulmen-Den Broeder
Eline van Dulmen-Den Broeder
GKGertjan Jl Kaspers
Gertjan Jl Kaspers

1 December 2017 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
NDNathan Duong
Nathan Duong
HDHailey Davis
Hailey Davis
PRPaula D. Robinson
Paula D. Robinson
SOSapna Oberoi
Sapna Oberoi
DCDanielle Cataudella
Danielle Cataudella
LSLillian Sung
Lillian Sung

1 January 2010 in Scandinavian Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
UHU Holzer
U Holzer
ARA van Royen-Kerkhof
A van Royen-Kerkhof
PTPatrick van der Torre
Patrick van der Torre
JKJ Kuemmerle-Deschner
J Kuemmerle-Deschner
CWC Well
C Well
NWN Wulffraat
N Wulffraat
Juvenile dermatomyositis (JDM) is a chronic inflammatory disorder of unknown aetiology that affects muscle and skin. We report on two patients with severe progressive JDM who developed contractures and were wheelchair dependent despite therapy including methotrexate (MTX), steroids, immunoglobulins, cyclosporin A, and rituximab. On account of the refractory disease, autologous stem cell transplantation (ASCT) was performed using a CD3/CD19-depleted graft after immunoablative conditioning with fludarabine, cyclophosphamide, and anti-thymocyte globulin. This induced a dramatic improvement and sustained remission of the disease in both patients. We demonstrate that ASCT is a therapeutic option with low toxicity for patients with severe, refractory JDM.